Glofitamab in Chinese Patients With R/R DLBCL

This study is testing glofitamab — a type of immune therapy called a bispecific antibody that helps your immune system find and destroy cancer cells — in Chinese patients with diffuse large B-cell lymphoma (DLBCL) that has come back or stopped responding to treatment. **You may be eligible if...** - You have been diagnosed with DLBCL confirmed by biopsy - Your lymphoma has relapsed (come back) or did not respond to at least two prior treatment regimens - You have measurable disease visible on scans **You may NOT be eligible if...** - You are pregnant or breastfeeding - You have a known active infection or a reactivated latent infection - You have an active autoimmune disease or immune deficiency - You have severe organ problems (poor heart function, poor lung function, low kidney function, or high bilirubin) Talk to your doctor to see if this trial is right for you.